Xin Tan, MD
Internal Medicine · Flushing, NYNPI 1235117979
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ardelyx, Inc.$1K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$692
- Amarin Pharma, Inc.$685
- Novo Nordisk$608
- Nestle Healthcare Nutrition Inc.$378
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,479100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ardelyx, Inc. | 64 | $1,247 |
| AbbVie(2 entities) | 63 | $1,020 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $692 |
| Amarin Pharma, Inc. | 44 | $685 |
| Novo Nordisk | 33 | $608 |
| Nestle Healthcare Nutrition Inc. | 20 | $378 |
| Gilead | 14 | $278 |
| Amgen(2 entities) | 12 | $251 |
| Kowa Pharmaceuticals America, Inc. | 12 | $195 |
| Merck | 9 | $167 |
| Phathom Pharmaceuticals, Inc. | 7 | $147 |
| Ironwood Pharmaceuticals, Inc | 7 | $141 |
| Astellas Pharma US Inc | 4 | $88 |
| Sumitomo Pharma America, Inc. | 3 | $70 |
| Boehringer Ingelheim | 3 | $59 |
| Pfizer | 2 | $54 |
| Cranial Technologies, Inc | 3 | $47 |
| AstraZeneca | 2 | $40 |
| Lilly USA, LLC | 2 | $38 |
| Johnson & Johnson | 2 | $36 |
| IBSA Pharma Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Fresenius USA Marketing, Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $19 |
| Sobi, Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,485 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Epolamine | 712 | $503,392 |
| VascepaIcosapent Ethyl | 1,246 | $445,157 |
| CreonLipase/Protease/Amylase | 294 | $262,823 |
| RestasisCyclosporine | 319 | $231,678 |
| Diclofenac Sodium | 331 | $195,261 |
| IbsrelaTenapanor Hcl | 98 | $181,671 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 88 | $127,400 |
| RybelsusSemaglutide | 110 | $115,765 |
| JanumetSitagliptin Phos/Metformin Hcl | 162 | $95,782 |
| Lactulose | 89 | $45,179 |
| MyrbetriqMirabegron | 92 | $44,235 |
| JanuviaSitagliptin Phosphate | 74 | $41,315 |
| Diflorasone Diacetate | 79 | $40,144 |
| Tacrolimus | 138 | $39,070 |
| Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag | 56 | $38,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Restasis, Linzess | $1,020 | $522,911668 claims |
| Ardelyx, Inc.Ibsrela | $1,247 | $181,67198 claims |
| MerckJanumet, Januvia | $167 | $137,096236 claims |
| Novo NordiskRybelsus | $608 | $115,765110 claims |
| Astellas Pharma US IncMyrbetriq | $88 | $44,23592 claims |
| GileadVemlidy | $278 | $36,73726 claims |
| Johnson & JohnsonXarelto | $36 | $33,69058 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $40 | $32,24360 claims |
| Boehringer IngelheimJardiance | $59 | $31,41740 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $147 | $25,90640 claims |
| PfizerEliquis | $54 | $20,22531 claims |
| Lilly USA, LLCTrulicity | $38 | $12,78013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Flushing
- Weining LiangFlushing$133K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.